Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35456040)

  • 1. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway.
    Li Y; Yang S; Yang S
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signaling.
    Li Y; Yang S; Liu Y; Yang S
    MedComm (2020); 2022 Jun; 3(2):e131. PubMed ID: 35615117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
    Zucchini C; Manara MC; Cristalli C; Carrabotta M; Greco S; Pinca RS; Ferrari C; Landuzzi L; Pasello M; Lollini PL; Gambarotti M; Donati DM; Scotlandi K
    J Exp Clin Cancer Res; 2019 Dec; 38(1):503. PubMed ID: 31878963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling.
    Li Y; Yang S; Liu Y; Yang S
    Cell Death Dis; 2022 Jun; 13(6):570. PubMed ID: 35760773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
    Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
    BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
    Dong L; Lin F; Wu W; Liu Y; Huang W
    Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.
    Quan Y; Li Z; Zhu K; Liang J
    Lipids Health Dis; 2021 Jul; 20(1):74. PubMed ID: 34304741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling.
    Xu Q; Zhuo K; Zhang X; Zhen Y; Liu L; Zhang L; Gu Y; Jia H; Chen Q; Liu M; Dong J; Zhou MS
    Eur J Pharmacol; 2024 Jan; 962():176252. PubMed ID: 38061470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inhibition of YAP/TAZ alters the biological behaviours of keloid fibroblasts.
    Gao N; Lu L; Ma X; Liu Z; Yang S; Han G
    Exp Dermatol; 2022 Mar; 31(3):320-329. PubMed ID: 34623712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the relationship of YAP and FAK in hMSCs and osteosarcoma cells: Discrimination of FAK modulation by nuclear YAP depletion or YAP silencing.
    Husari A; Steinberg T; Dieterle MP; Prucker O; Rühe J; Jung B; Tomakidi P
    Cell Signal; 2019 Nov; 63():109382. PubMed ID: 31376525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling.
    Li Y; Liu M; Yang S; Fuller AM; Karin Eisinger-Mathason TS; Yang S
    Oncogene; 2021 Apr; 40(14):2553-2566. PubMed ID: 33686240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.
    Wu X; Xiang H; Cong W; Yang H; Zhang G; Wang Y; Guo Z; Shen Y; Chen B
    Biochem Biophys Res Commun; 2020 Jun; 527(1):29-36. PubMed ID: 32446383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
    Fusco P; Mattiuzzo E; Frasson C; Viola G; Cimetta E; Esposito MR; Tonini GP
    Eur J Pharmacol; 2021 Feb; 893():173829. PubMed ID: 33347823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines.
    Ferraiuolo M; Pulito C; Finch-Edmondson M; Korita E; Maidecchi A; Donzelli S; Muti P; Serra M; Sudol M; Strano S; Blandino G
    Cancer Lett; 2018 Oct; 433():18-32. PubMed ID: 29933048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
    Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
    J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
    Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
    Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.